ライフサイエンスコーパス: histone deacetylase

1 homologue of SIR2 is SIRT1, an NAD-dependent histone deacetylase.

2 a Pol II promoter-proximal pausing-dedicated histone deacetylase.

3 lencing and show it to encode a sirtuin-type histone deacetylase.

4 chimera (PROTAC), which efficiently degrades histone deacetylases.

5 metalloproteases, nitrilases, caspases, and histone deacetylases.

6 is relieved by pharmacological inhibition of histone deacetylases.

7 ctor Zelda, and lack of SIN3A and associated histone deacetylases.

8 same SEs also harbor the greatest amounts of histone deacetylases.

9 t instead were associated with inhibition of histone deacetylases.

10 ein kinase C; nor do they inhibit class I/II histone deacetylases.

11 tone H3 (H3), acetylated histone H3 (AC-H3), histone deacetylase 1 (HDAC)1, tumor necrosis factor-alp

12 Histone deacetylase 1 (HDAC1) and HDAC2 are responsible

13 icient B cells had decreased accumulation of histone deacetylase 1 (HDAC1) and HDAC2 at the Cd86 locu

14 and SOX11 expression was also observed after histone deacetylase 1 (HDAC1) or HDAC2 was depleted by R

15 of HBx, histone acetyl-transferase P300 and histone deacetylase 1 (HDAC1) to circularized HBV DNA (w

16 NLK can directly phosphorylate histone deacetylase 1 (HDAC1), as well as T cell factor/

17 sis-stimulating of P53 protein 2 (ASPP2) and histone deacetylase 1 (HDAC1), were also identified.

18 Deletion of ARID1A resulted in loss of histone deacetylase 1 binding, increased histone 4 lysin

19 hreonine cluster promoted the recruitment of histone deacetylase 1 to specific target gene promoters

20 pha-dependent transcriptional repression via histone deacetylase 1-mediated histone deacetylation.

21 ity and can also be induced by inhibition of histone deacetylases 1 and 2 (HCAC 1/2), which is one of

22 Here we report that histone deacetylase 10 (HDAC10) might function as a puta

23 ular interest, pharmacological inhibition of histone deacetylase 11 (HDAC11) and suppressor of varieg

24 Our finding that high levels of histone deacetylase 11 (HDAC11) in human lung tumor tiss

25 hippocampus, NPTP correlated with decreased histone deacetylase 11 (HDAC11), a transcriptional repre

26 d by the expression of a chromatin modifier, histone deacetylase 11 (HDAC11).

27 show that bacterial-derived lactate inhibits histone deacetylase 11, causing unchecked HDAC6 activity

28 ressor complexes containing PRMT5 and either histone deacetylase 2 (HDAC2) or HDAC3, enhanced binding

29 l splicing variant in the mouse kidney) with histone deacetylase 2 (HDAC2), as well as the function o

30 tipsychotic treatment is mediated mostly via histone deacetylase 2 (HDAC2).

31 AR formed a repressive complex by recruiting histone deacetylase 2 to the SIRT3 promoter, and depleti

32 progression, where it interacts with class I histone deacetylases 2 and 3 (HDAC2 and HDAC3) to regula

33 robiota-derived inositol phosphate regulates histone deacetylase 3 (HDAC3) activity in the intestine.

34 the nuclear receptor corepressor (NCOR) and histone deacetylase 3 (HDAC3) complex, has a central rol

35 o macrophage differentiation program through histone deacetylase 3 (HDAC3) inhibition.

36 Here, we show that histone deacetylase 3 (HDAC3) is a key epigenetic factor

37 Histone deacetylase 3 (Hdac3) is a target of the FDA app

38 We found that histone deacetylase 3 (HDAC3) is critical for the develo

39 or genetic manipulations, we determined that histone deacetylase 3 (HDAC3) negatively regulates Nr4a2

40 Histone deacetylase 3 (Hdac3) regulates the expression o

41 rg1) expression through interaction with the histone deacetylase 3 (HDAC3)-nuclear receptor corepress

42 e reporter assay developed, we find that the histone deacetylase 3 (HDAC3)-selective inhibitor, RGFP9

43 rhythms in the mouse small intestine through histone deacetylase 3 (HDAC3).

44 ng RUNX1 and recruiting corepressors such as histone deacetylase 3 (HDAC3).

45 on of CCAR2 diminished its interactions with histone deacetylase 3 and beta-catenin, interfering with

46 SMRT) regulate gene expression by activating histone deacetylase 3 through their deacetylase activati

47 Histone deacetylases 3 (HDAC3) modulates the acetylation

48 his transcription factor acts along with the histone deacetylases 3 and 8 to regulate the induction o

49 xis identified the transcriptional repressor histone deacetylase 4 (HDAC4) as an upstream regulator o

50 Here, we identified a histone deacetylase 4 (HDAC4) subdomain as a molecular c

51 Histone deacetylase 5 (HDAC5) and HDAC9 are class IIa HD

52 entiation via the protein kinase Cmu (PKCmu)/histone deacetylase 5 (HDAC5)/myocyte-specific enhancer

53 cription factor IIIC subunit 4 and decreased histone deacetylase 5 expression.

54 c) expression via the protein kinase C (PKC)/histone deacetylase 5-mediated pathway.

55 G3BP1 acetylation is regulated by histone deacetylase 6 (HDAC6) and CBP/p300.

56 s, SGs can sequester the proteostasis factor histone deacetylase 6 (HDAC6) and thereby impede TDP-43

57 Inhibition of histone deacetylase 6 (HDAC6) has emerged as a promising

58 favorable cap group for potent and selective histone deacetylase 6 (HDAC6) inhibitors.

59 Histone deacetylase 6 (HDAC6) is a multidomain cytosolic

60 Histone deacetylase 6 (HDAC6) is a peculiar HDAC isoform

61 Histone deacetylase 6 (HDAC6) is an emerging target for

62 Selective inhibition of histone deacetylase 6 (HDAC6) is being recognized as a t

63 Furthermore, the dynein adapter histone deacetylase 6 (HDAC6) is indispensable for the m

64 Histone deacetylase 6 (HDAC6) primarily catalyzes the re

65 Inhibition of histone deacetylase 6 (HDAC6) suppresses the growth of A

66 iting the microtubule-associated deacetylase histone deacetylase 6 (HDAC6) via a signaling pathway in

67 Inhibition of histone deacetylase 6 (HDAC6) was shown to support axon

68 we report that MLH1 is a novel substrate of histone deacetylase 6 (HDAC6).

69 The uncoating process is facilitated by histone deacetylase 6 (ref.(1)).

70 sh1 reprogramming is dependent on functional HISTONE DEACETYLASE 6 and methyltransferase MET1, and tr

71 eases INF2 inhibition, whereas inhibitors of histone deacetylase 6 block the activation of cellular I

72 cluding DNA methyltransferase inhibitors and histone deacetylase 6 inhibitors (DNMTis and HDAC6is) in

73 Ursodeoxycholic acid (UDCA) and histone deacetylase 6 inhibitors (HDAC6is) have arisen a

74 eatment of CAP-KAc-actin-inhibited INF2 with histone deacetylase 6 releases INF2 inhibition, whereas

75 ompanied by MT destabilization and increased histone deacetylase-6 (HDAC6) activity resulting from el

76 serve as selective competitive inhibitors of histone deacetylase-6 (HDAC6).

77 ound that SIK1 phosphorylated and stabilized histone deacetylase 7 (HDAC7) protein during cardiac str

78 , and UV irradiation leads to an increase in histone deacetylase 8 (HDAC8) activity and the adoption

79 ns of the structurally characterized isozyme histone deacetylase 8 (HDAC8).

80 -resistant metastatic state was dependent on histone deacetylase 8 activity.

81 Silencing of histone deacetylase 8 led to the inhibition of EphA2 and

82 onstrate that the chromatin-modifying enzyme HISTONE DEACETYLASE 9 (HDA9) mediates thermomorphogenesi

83 es have identified a prominent role of HDAC (histone deacetylase)-9 in atherosclerosis and its clinic

84 that miR-335 is epigenetically regulated by histone deacetylases; a screen for suitable histone deac

85 Inhibition of histone deacetylases abates c-MYC binding to the promote

86 then increases NAD+ levels and activates the histone deacetylase activity of SIRT1.

87 this context are largely independent of its histone deacetylase activity.

88 Selective inhibition of class IIa histone deacetylases alleviates renal fibrosis.

89 Hsp90, and kinases) and functionally (e.g., histone deacetylases and proteasome) connected to many v

90 omising target associations involving HDACs (histone deacetylases) and sigma receptors by employing m

91 N; PuHox52 repressed PuHDA9, which encodes a histone deacetylase, and led to an increase in acetylati

92 recruitment of ciliary membrane components, histone deacetylase, and transcription factors.

93 ng transcription factors, Mediator subunits, histone deacetylases, and histone tails.

94 ins, disruption of cytoskeletal proteins via histone deacetylases, and the recently discovered DNA da

95 y-as well as with nucleosome remodellers and histone deacetylases-at active enhancers and promoters.

96 cation proteins, histone acetyltransferases, histone deacetylases, BET bromodomain proteins, protein

97 available small-molecule inhibitor targeting histone deacetylase class I, is currently in clinical ev

98 disrupt heterochromatin by outcompeting the histone deacetylase, Clr3 from sites of heterochromatin

99 netic interactions link Cdk9, H2Bub1 and the histone deacetylase Clr6-CII, while combined Cdk9 inhibi

100 onsistent with the known control of the Set3 histone deacetylase complex (HDAC) by H3K4 di-methylatio

101 study uncovers a previously uncharacterized histone deacetylase complex in plant immunity and highli

102 t cyclin C-Cdk8, together with the Ume6-Rpd3 histone deacetylase complex, represses the essential aut

103 elegans CFP-1 and an Rpd3/Sin3 small (SIN3S) histone deacetylase complex.

104 pression works through the loss of the Rpd3L histone deacetylase complex.

105 chromatin structure through the activity of histone deacetylase complexes (HDACs).

106 Class I histone deacetylase complexes play essential roles in ma

107 teracting with the nucleosome remodeling and histone deacetylase complexes.

108 In the heart, HDACs (histone deacetylases) control remodeling associated proc

109 ple-action prodrugs with known inhibitors of histone deacetylase, cyclooxygenase, and pyruvate dehydr

110 ferentiation into fibroblast-like cells in a histone deacetylase-dependent manner.

111 ugs for three distinct epi-drugs that target histone deacetylase, DNA methylation and bromodomain pro

112 The histone deacetylase domain of HDA15 (HDA15HD) assembles

113 00 acetylated FUS, whereas both sirtuins and histone deacetylases families of lysine deacetylases con

114 ied AMI-MS to identify inhibitors of a human histone deacetylase from AstraZeneca's collection of 2 m

115 ated by histone acetyltransferases (HAT) and histone deacetylases, have been recognized as major regu

116 his study we investigated how the absence of histone deacetylase HDA-2 in the Trichoderma atroviride

117 Genetic interaction between kin-29 and the histone deacetylase hda-4 coupled with subcellular local

118 ing (1) auxin/indole-3-acetic acid (AUX/IAA)-histone deacetylase (HDA) and (2) auxin response factor

119 ing (1) auxin/indole-3-acetic acid (AUX/IAA)-histone deacetylase (HDA) and (2) auxin response factor

120 stone Deacetylase1 (RPD3/HDA1) type class II histone deacetylase HDA15 in Arabidopsis (Arabidopsis th

121 ruits core and putative elements of the BRAF-histone deacetylase (HDAC) (BHC) chromatin-remodeling co

122 h two distinct mechanisms: the inhibition of histone deacetylase (HDAC) activity and the activation o

123 Histone deacetylase (HDAC) activity has been identified

124 Pharmacological inhibition of Histone Deacetylase (HDAC) activity restores histone H3

125 sociated with VPA-mediated inhibition of the histone deacetylase (HDAC) and glycogen synthase kinase-

126 present study, a series of novel dual-target histone deacetylase (HDAC) and mammalian target of rapam

127 ase complex (MiDAC) is a recently identified histone deacetylase (HDAC) complex.

128 Histone deacetylase (HDAC) enzymes play a crucial role e

129 onserved histone acetyltransferase (HAT) and histone deacetylase (HDAC) enzymes that were first chara

130 coded by Tcf7, is a transcription factor and histone deacetylase (HDAC) essential for commitment to b

131 nstate the critical period of plasticity via histone deacetylase (HDAC) inhibition, caused adult stre

132 trongly and consistently modulated following histone deacetylase (HDAC) inhibition; three (H1F0, IRGM

133 the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared.

134 We here report that a small-molecule Class 1 histone deacetylase (HDAC) inhibitor Entinostat (MS-275)

135 ator C/EBPdelta decreases sensitivity to the histone deacetylase (HDAC) inhibitor panobinostat.

136 e acetylation and neutralized effects of the histone deacetylase (HDAC) inhibitor romidepsin.

137 be rescued by exogenous betaOHB and class I histone deacetylase (HDAC) inhibitor treatment.

138 transferase (DNMT) inhibitor hydralazine and histone deacetylase (HDAC) inhibitor valproic acid (VPA)

139 The histone deacetylase (HDAC) inhibitor vorinostat disrupts

140 hase mRNA expression in cells treated with a histone deacetylase (HDAC) inhibitor was accompanied by

141 ylation, we found that trichostatin A, a pan-histone deacetylase (HDAC) inhibitor, blocked all high g

142 olium castaneum TcA cells, Trichostatin A, a histone deacetylase (HDAC) inhibitor, mimics juvenile ho

143 the effect of MC1568, a selective class IIa histone deacetylase (HDAC) inhibitor, on the development

144 ituted tumor cells are more sensitive to the histone deacetylase (HDAC) inhibitor-induced loss of ste

145 ent can affect weight gain by elimination of histone deacetylase (HDAC) inhibitor-producing microbes,

146 ever-growing body of evidence has shown that histone deacetylase (HDAC) inhibitors (HDACi) can have s

147 Histone deacetylase (HDAC) inhibitors (HDACis) have been

148 es based on DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors are currently in u

149 Histone deacetylase (HDAC) inhibitors are effective in k

150 city, and memory.SIGNIFICANCE STATEMENT Some histone deacetylase (HDAC) inhibitors are known to have

151 There is increasing evidence that histone deacetylase (HDAC) inhibitors can (re)sensitize

152 stat, vorinostat) and selective (romidepsin) histone deacetylase (HDAC) inhibitors elicited metabolic

153 The discovery of isozyme-selective histone deacetylase (HDAC) inhibitors is critical for un

154 Histone deacetylase (HDAC) inhibitors may have therapeut

155 r the first time that retinoic acid (RA) and histone deacetylase (HDAC) inhibitors, including short-c

156 ation with Ac(5)Neu5Ac combined with various histone deacetylase (HDAC) inhibitors, including vorinos

157 ighly sensitive to DNA methyltransferase and histone deacetylase (HDAC) inhibitors.

158 emethylase 1 (LSD1) sensitizes DIPG cells to histone deacetylase (HDAC) inhibitors.

159 and anxiety by restoring hippocampal class I histone deacetylase (HDAC) levels and activity, specific

160 get bromodomain and extra-terminal (BET) and histone deacetylase (HDAC), potentially serving as promi

161 G-protein receptor 41 (GPR41) and inhibiting histone deacetylase (HDAC).

162 mutant leukemia cells were more sensitive to histone deacetylase (HDAC)6 inhibition than JAK3 mutant

163 Pharmacological modulation of class I histone deacetylases (HDAC) has been evaluated as a ther

164 In turn, ROCKI-APEX1 recruited the histone deacetylase HDAC1, which removed the H3K27ac mod

165 Twist2, which bound to the promoters of the histone deacetylases HDAC1 and HDAC3 and induced HDAC1 a

166 Recently, we identified that histone deacetylases HDAC1 and HDAC7 are necessary to ma

167 N-terminal KER domain to associate with the histone deacetylases HDAC1/2 and the histone demethylase

168 sferase Tip60 acetylates eEF1A1, whereas the histone deacetylase HDAC2 deacetylates eEF1A1.

169 its the lysine-specific demethylase Lsd1 and histone deacetylase Hdac2, resulting in the simultaneous

170 factor MutSbeta (Msh2-Msh3 complex) and the histone deacetylase HDAC3 function in the same pathway t

171 Further, we show that Nr4a2 is regulated by histone deacetylase HDAC3 in the aged mouse hippocampus.

172 Here we show that the histone deacetylase HDAC3 inhibits CD8 T cell cytotoxici

173 Previous studies examining the role of the histone deacetylase Hdac3 within myeloid cells demonstra

174 nal nuclear protein that associates with the histone deacetylase HDAC3.

175 Here we report that class II histone deacetylases HDAC4 and HDAC5 associate with TBX5

176 Here, we report that class IIa histone deacetylases (HDAC4 and HDAC5) are required for

177 ANG II enhanced the activities of Class I histone deacetylases (HDACs 1/2), thereby decreased hist

178 The constitutively nuclear histone deacetylases (HDACs) 1, 2, and 3 erase acetyl ma

179 ion co-regulators physically associated with histone deacetylases (HDACs) and many known players in A

180 KSHV gene expression, we found that several histone deacetylases (HDACs) and sirtuins (SIRTs), inclu

181 The histone deacetylases (HDACs) are a superfamily of chroma

182 Histone deacetylases (HDACs) are an attractive therapeut

183 Histone deacetylases (HDACs) are enzymes that regulate c

184 Additionally, we find that histone deacetylases (HDACs) are essential for CR TF tra

185 Histone deacetylases (HDACs) are important regulators of

186 Histone deacetylases (HDACs) are involved in diverse cel

187 Histone deacetylases (HDACs) are key enzymes in epigenet

188 tory activity in the nanomolar range against histone deacetylases (HDACs) as the key target for SAHA.

189 Histone deacetylases (HDACs) have been shown to alleviat

190 AR-42 is an orally active inhibitor of histone deacetylases (HDACs) in clinical trials for mult

191 Histone deacetylases (HDACs) perform multiple functions

192 Like many histone modifying enzymes, histone deacetylases (HDACs) play critical roles in gove

193 Class IIa histone deacetylases (HDACs) repress cardiomyocyte hyper

194 Mammalian histone deacetylases (HDACs) undergo phosphorylation to

195 The histone deacetylases (HDACs), a family of 18 host enzyme

196 n vivo expression of the epigenetic enzymes, histone deacetylases (HDACs), across healthy human aging

197 the Mbd3/NuRD complex and the activities of histone deacetylases (HDACs), and Tet2 hydroxylase play

198 atment of lymphomas, including inhibitors of histone deacetylases (HDACs), DNA methyltransferases (DN

199 While in mammals, histone deacetylases (HDACs), histone H3 lysine 9 methyl

200 ity of histone acetyltransferases (HATs) and histone deacetylases (HDACs), is necessary for appropria

201 a deficit in PTSD, by (1) altering class IIa histone deacetylases (HDACs), which integrate effects of

202 ucture and gene expression and is removed by histone deacetylases (HDACs).

203 , and repressed CPI-17 transcription through histone deacetylases (HDACs).

204 appears to be mediated through the class IIa histone deacetylases (HDACs).

205 ression of inhibitors of STAT3, particularly histone deacetylases (HDACs).

206 e in histone acetylation via deactivation of histone deacetylases (HDACs).

207 d regulating gene expression, is mediated by histone deacetylases (HDACs).

208 ta strain, deficient in the NAD(+)-dependent histone deacetylase Hst1, which inhibits de novo NAD(+)

209 We have elucidated a role for the Sir2 histone deacetylase in establishing the normal distribut

210 YY1 deletion abrogated its interaction with histone deacetylases in astrocytes.

211 epidermal development, but the functions of histone deacetylases in this context are poorly understo

212 ate the crucial role of HDAC6, a cytoplasmic histone deacetylase, in driving RMS tumor growth, self-r

213 likely to benefit from immune-checkpoint and histone deacetylase inhibition (NCT02395627).

214 our approach, we have discovered that rapid histone deacetylase inhibition disrupts super enhancer f

215 eroids through mechanisms possibly involving histone deacetylase inhibition.

216 We now show that the FDA-approved histone deacetylase inhibitor (HDACi) valproic acid (VPA

217 In this study romidepsin, a potent histone deacetylase inhibitor (HDACi), induced apoptosis

218 using Bruton's tyrosine kinase inhibitor and histone deacetylase inhibitor abrogated refractory B-1b

219 Belinostat (BEL), a histone deacetylase inhibitor approved for the treatment

220 Here, we show that the histone deacetylase inhibitor drug, vorinostat, in addit

221 n line with this finding, treatment with the histone deacetylase inhibitor givinostat caused a signif

222 ected pharmaceutical residues in water, is a histone deacetylase inhibitor in mammals, and is reporte

223 ed with treatment of melanoma cells with the histone deacetylase inhibitor LBH589.

224 e CDK7/super-enhancer inhibitor THZ1 and the histone deacetylase inhibitor panobinostat synergistical

225 amine-based Pt(IV) derivative containing the histone deacetylase inhibitor rac-2-(2-propynyl)octanoat

226 Romidepsin (RMD) is a histone deacetylase inhibitor reported to reverse HIV-1

227 C, we studied the effect of the FDA-approved histone deacetylase inhibitor suberanilohydroxamic acid

228 Degradation of Dnmt1 by the histone deacetylase inhibitor suberoylanilide hydroxamic

229 ethyltransferase inhibitor decitabine or the histone deacetylase inhibitor tacedinaline on NET cells

230 While butyrate is a known histone deacetylase inhibitor that activates expression

231 Pretreatment with trichostatin A, a pan-histone deacetylase inhibitor that renders chromatin dec

232 Histone deacetylase inhibitor treatment significantly re

233 (SIRT) inhibitor nicotinamide but not by the histone deacetylase inhibitor trichostatin A.

234 conducted to investigate the effects of the histone deacetylase inhibitor valproate and all-trans re

235 The histone deacetylase inhibitor valproic acid (VPA) is kno

236 o receive ART-only (control) or ART plus the histone deacetylase inhibitor vorinostat (the kick) and

237 We performed two phase I trials of the histone deacetylase inhibitor vorinostat combined with e

238 and can be re-activated with Trichostatin A (histone deacetylase inhibitor) and/or 5-aza-dC (an inhib

239 ecitabine (demethylating agent) or butyrate (histone deacetylase inhibitor) restored hOCT1 expression

240 ted with both calcitriol and trichostatin A (histone deacetylase inhibitor), the level of IL-9 reache

241 (3C) consisting of sodium butyrate (a broad histone deacetylase inhibitor), UNC0646 (a histone methy

242 A histone deacetylase inhibitor, TSA, stimulated Rgs16::GF

243 are a prerequisite during the cell cycle and histone deacetylase inhibitor-mediated therapeutics.

244 lation and mimicked by trichostatin A, a pan-histone deacetylase inhibitor.

245 n as chidamide) is an oral subtype-selective histone deacetylase inhibitor.

246 intensity in the nucleus increased following histone-deacetylase inhibitor treatment.

247 ased on the well-established synergy between histone deacetylase inhibitors (HDACi) and alkylating ag

248 roylanilide hydroxamic acid (vorinostat) are histone deacetylase inhibitors (HDACi) approved by the U

249 Histone deacetylase inhibitors (HDACi) are largely ineff

250 Histone deacetylase inhibitors (HDACi) are the most wide

251 previously showed that 2-aminobenzamide-type histone deacetylase inhibitors (HDACi) increase FXN mRNA

252 Clinical trials investigating histone deacetylase inhibitors (HDACi) to reverse HIV-1

253 efforts has been on a class of drugs called histone deacetylase inhibitors (HDACi), which have the p

254 5) inhibited tail regeneration, including 18 histone deacetylase inhibitors (HDACi).

255 ch as molecularly targeted agents, including histone deacetylase inhibitors (HDACi).

256 Histone deacetylase inhibitors (HDACIs) may overcome end

257 compared with interferon-alpha (P = .0067), histone deacetylase inhibitors (P = .0003), novel immuno

258 Based on the synergism between histone deacetylase inhibitors and hypomethylating agent

259 st HDACi pharmacological activity.IMPORTANCE Histone deacetylase inhibitors are widely studied HIV la

260 identifies cell types that are sensitive to histone deacetylase inhibitors based on their metabolic

261 Histone deacetylase inhibitors have been demonstrated to

262 histone deacetylases; a screen for suitable histone deacetylase inhibitors identified belinostat as

263 on, which can be reactivated by a mixture of histone deacetylase inhibitors in combination with TNF.

264 ne perturbations could reduce sensitivity to histone deacetylase inhibitors in SS patients.

265 ination with other epigenetic drugs, such as histone deacetylase inhibitors or differentiation induce

266 e further amplified by DNA demethylation and histone deacetylase inhibitors providing an exquisite th

267 In particular, our results with histone deacetylase inhibitors support the view that chr

268 that uses low-dose DNA methyltransferase and histone deacetylase inhibitors, 5-azacytidine and entino

269 Histone deacetylase inhibitors, including valproic acid,

270 death in CTCL especially when combined with histone deacetylase inhibitors.

271 bination of PI3K-alpha/delta inhibitors with histone deacetylase inhibitors.

272 ns using a combination of the checkpoint and histone deacetylase inhibitors.See related article by Fu

273 to fitness of the individual in response to histone deacetylases inhibitors (HDACi).

274 gents against colorectal cancer due to their histone deacetylases inhibitory properties, which induce

275 Additionally, pentanoate shows a potent histone deacetylase-inhibitory activity in CD4(+) T cell

276 inhibitors of epigenetic processes, such as histone deacetylases, methylases and demethylases, can e

277 ulation also correlated with enhanced HDAC4 (histone deacetylase) nuclear export, creating a microdom

278 y component of the nucleosome remodeling and histone deacetylase (NuRD) complex in early B cells.

279 How histone deacetylases perform specialized molecular and b

280 Inhibition of histone deacetylases promoted accessible chromatin withi

281 We find compounds that inhibit histone deacetylase proteins (HDACs) are effective in no

282 Histone deacetylases remove acetyl groups from histone p

283 Germline depletion of histone deacetylases revealed that other acetyl marks ca

284 The histone deacetylase Rpd3, suggested to have a role in Wh

285 Here, we report that the Set3C histone deacetylase scaffold Snt1 can act as a prion tha

286 e-distant sequences, and is modulated by the histone deacetylase Sir2 and the nucleoporin Nup2.

287 Here, we demonstrate that the histone deacetylase SIRT6 binds to Pol II and prevents t

288 Unique among histone deacetylases, SIRT6 possesses the intrinsic capa

289 NAM is a transient inhibitor of class III histone deacetylase SIRTs (silent mating type informatio

290 he key epigenetic modulators, NAD+ dependent histone deacetylase Sirtuin 2 (SIRT2), which upon infect

291 The class III histone deacetylase sirtuin 6 (SIRT6) modulates numerous

292 The histone deacetylase sirtuin 6 (SIRT6) regulates numerous

293 heir effect on the enzymatic activity of the histone deacetylase sirtuin family (SIRT1, SIRT2, SIRT3,

294 deacetylase sirtuin-1 (SIRT1) is a class III histone deacetylase that positively regulates cancer-rel

295 pigenetic rheostat orchestrated by c-MYC and histone deacetylases that inhibits lysosomal and autopha

296 lation was coupled to a switch from type IIa histone deacetylase to p300 histone acetylase binding th

297 erived metabolite that activates a mammalian histone deacetylase to promote epithelial repair.

298 multi-protein complexes that recruit class I histone deacetylases to the genome to regulate gene expr

299 uclear/cytosolic expression ratio for HDAC4 (histone deacetylase type-4).

300 We observed that histone deacetylases were critical targets to tune expre